1. Anti-Semaphorin 3A neutralization monoclonal antibody prevents sepsis development in lipopolysaccharide-treated mice
- Author
-
Shu-ichi Hashimoto, Wataru Ohkubo, Miyuki Ogawara, Chie Hotta, Koji Murakami, Sasakura Yukie, Toru Tsuji, Tomomi Araki, Takashi Yabuki, Hiromi Okumura, Naoya Yamashita, Aoi Jitsuki-Takahashi, Aki Takaiwa, Tomohiko Tamura, Chika Koyama, and Yoshio Goshima
- Subjects
Lipopolysaccharides ,Male ,medicine.drug_class ,Immunology ,Biology ,Monoclonal antibody ,Neutralization ,Cell Line ,Sepsis ,Mice ,Immune system ,Semaphorin ,In vivo ,Chlorocebus aethiops ,medicine ,Immunology and Allergy ,Animals ,Humans ,Antibodies, Monoclonal ,SEMA3A ,Semaphorin-3A ,General Medicine ,medicine.disease ,Antibodies, Neutralizing ,Recombinant Proteins ,Mice, Inbred C57BL ,COS Cells ,biology.protein ,Antibody ,Chickens - Abstract
Semaphorin 3A (Sema3A), originally identified as a potent growth cone collapsing factor in developing sensory neurons, is now recognized as a key player in immune, cardiovascular, bone metabolism and neurological systems. Here we established an anti-Sema3A monoclonal antibody that neutralizes the effects of Sema3A both in vitro and in vivo. The anti-Sema3A neutralization chick IgM antibodies were screened by combining an autonomously diversifying library selection system and an in vitro growth cone collapse assay. We further developed function-blocking chick-mouse chimeric and humanized anti-Sema3A antibodies. We found that our anti-Sema3A antibodies were effective for improving the survival rate in lipopolysaccharide-induced sepsis in mice. Our antibody is a potential therapeutic agent that may prevent the onset of or alleviate symptoms of human diseases associated with Sema3A.
- Published
- 2014